Suscriptores   Asóciese  
Textos Completos Autorizados
ESTUDIO DE ADN DE PAPILOMAVIRUS HUMANO PARA EL MANEJO DE MUJERES CON CELULAS ESCAMOSAS ATIPICAS EN EL EXTENDIDO DE PAPANICOLAOU

v-estudie-lo-mejor.gif
Expertos Invitados





ESTUDIO DE ADN DE PAPILOMAVIRUS HUMANO PARA EL MANEJO DE MUJERES CON CELULAS ESCAMOSAS ATIPICAS EN EL EXTENDIDO DE PAPANICOLAOU

(especial para SIIC © Derechos reservados)
El estudio de ADN de HPV con el ensayo de captura híbrida de segunda generación es útil para predecir la existencia de neoplasia intraepitelial grados 2-3 en mujeres con ASCUS, con lo que disminuye el número de pacientes derivadas para colposcopia.
shlay.gif Autor:
Judith C. Shlay
Columnista Experto de SIIC
Artículos publicados por Judith C. Shlay
Recepción del artículo
21 de Noviembre, 2002 		Primera edición
4 de Marzo, 2003 		Segunda edición, ampliada y corregida
7 de Junio, 2021

ESTUDIO DE ADN DE PAPILOMAVIRUS HUMANO PARA EL MANEJO DE MUJERES CON CELULAS ESCAMOSAS ATIPICAS EN EL EXTENDIDO DE PAPANICOLAOU

Resumen
Este trabajo resume los hallazgos de una revisión de varios estudios que utilizaron el ensayo de captura híbrida II (CH II) para ADN de HPV con el fin de determinar la utilidad del empleo de la prueba de ADN de HPV para predecir neoplasia intraepitelial (CIN) grados 2-3 en las biopsias de mujeres que se presentan con células escamosas atípicas de significado incierto (ASCUS) en el extendido de Papanicolaou. Según nueve publicaciones, la sensibilidad del estudio de ADN de HPV para la detección de CIN 2-3 con ASCUS fue de 83% a 100%. El valor predictivo negativo de las pruebas de ADN de HPV para los tipos de alto riesgo fue de 98% o más. La especificidad varió entre 40% y 74%. Se identificaron tipos de HPV de alto riesgo en 31% a 60% de las mujeres con ASCUS, pero tal proporción disminuyó a medida que aumentaba la edad. El estudio de ADN de HPV con el ensayo CH II es útil para predecir la existencia de CIN 2-3 en mujeres con ASCUS, con lo que disminuye el número de pacientes derivadas para colposcopia.

Palabras clave
Papilomavirus humano (HPV), estudio de HPV, ASCUS, displasia cervical


Artículo completo
(castellano)
Extensión:  +/-6.34 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Human Papillomavirus DNA Testing for the Management of Women with Atypical Squamous Cells on Papanicolaou Smear

Abstract
This paper summarizes the findings of a literature review of various studies using the hybrid capture II assay (HC II) for HPV DNA testing to determine the utility of using the assay for HPV DNA testing to predict CIN 2-3 on biopsy in women presenting with atypical squamous cells of undetermined significance (ASC-US) on Papanicolaou smear. Based on nine publications, the sensitivity of HPV DNA testing for the detection of biopsy confirmed CIN 2-3 with ASC-US was 83%-100%. The negative predictive value of HPV DNA testing for high-risk types was 98% or greater. Specificity ranged between 40%-74%. Between 31% and 60% of all women with ASC-US had high-risk types of HPV identified, with the proportion decreasing with increasing age. HPV DNA testing using the HC II assay is useful for predicting CIN 2-3 in women with ASC-US and result in fewer women being referred to colposcopy.

Key words
Human papillomavirus (HPV), HPV testing, ASC-US, cervical dysplasia


Full text
(english)
 para suscriptores/ assinantes
Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Obstetricia y Ginecología
Relacionadas: Anatomía Patológica, Diagnóstico por Laboratorio, Oncología, Salud Pública



Comprar este artículo
Extensión: 6.34 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Bibliografía del artículo
  1. Parkin D, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
  2. International Agency for Research on Cancer (IARC) Working Group on the Evaluation of Carcinogenic Risks, Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 64. 1995, Lyons, France: World Health Organization.
  3. Bosch F, Manos M, Nunoz N, Sherman M, Jansen A, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
  4. Wright T, Cox J, Massad L, Twiggs L, Wilkinson E. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120-9.
  5. Kinney W, Manos M, Hurley L, Ransley J. Where\'s the high-grade cervical neoplasia The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol 1998;91:973-6.
  6. Paavonen J, Kiviat N, Wolner-Hannssen P, Stevens C, Vontver L, Brockway J, et al. Significance of mild cervical cytologic atypia in a sexually transmitted disease clinic population. Acta Cytol 1989;33:831-8.
  7. Etherington I, Shafi M. Human papillomavirus and cervical screening. Genitourin Med 1996;72:153-4.
  8. Solomon D, Davey D, Kurman R, Moriarty A, O\'Connor D, Prey M, et al. The 2001 Bethesda system. Terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
  9. Cox J, Lorincz A, Schiffman M, Sherman M, Cullen A, Kurman R. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995;172:946-54.
  10. Ferris D, Wright T, Litaker M, Richart R, Lorincz A, Sun X, et al. Triage of women with ASCUS and LSIL on Pap smear reports: Management by repeat Papanicolaou smear, HPV DNA testing, or colposcopy. J Fam Pract 1998;46:125-34.
  11. Wright T, Sun X, Koulos J. Comparison of management algorithms for evaluation of women with low-grade cytologic abnormalities. Obstet Gynecol 1995;85:202-10.
  12. Wright T, Lorincz A, Ferris D, Richart R, Ferenczy A, Mielzynska I, et al. Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. Am J Obstet Gynecol 1998;178:962-6.
  13. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9.
  14. Slawson D, Bennett J, Simon L, Herman J. Should all women with cervical atypia be referred for coloposcopy: A HARNET study. J Fam Pract 1994;38:387-92.
  15. Kobelin M, Kobelin C, Burke L, Lavin P, Niloff J, Kim Y. Incidence and predictors of cervical dysplasia in patients with minimally abnormal Papanicolaou smears. Obstet Gynecol 1998;92:356-9.
  16. Eskridge C, Begneaud W, Landwehr C. Cervicography combined with repeat Papanicolaou test as triage for low-grade cytologic abnormalities. Obstet Gynecol 1998;92:351-5.
  17. Jones B, Novis D. Follow-up of abnormal gynecologic cytology: A college of American pathologists Q-probes study of 16132 cases from 306 laboratories. Arch Pathol Lab Med 2000;124:665-71.
  18. Lonky N, Sadeghi M, Tsadik G, Petitti D. The clinical significance of the poor correlation of cervical dysplasia and cervical malignancy with referral cytological results. Am J Obstet Gynecol 1999;181:560-6.
  19. Schiffman M, Bauer H, Hoover R, Glass A, Cadell D, Rush B, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64.
  20. Ferris D, Wright T, Litaker M, Richard R, Lorincz A, Sun X, et al. Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL. J Fam Pract 1998;46:136-41.
  21. Hatch K, Schneider A, Abdel-Nour M. An evaluation of human papillomavirus testing for intermediate and high-risk types as triage before colposcopy. Am J Obstet Gynecol 1995;172:1150-7.
  22. Jenkins D, Sherlaw-Johnson C, Gallivan S. Assessing the role of HPV testing in cervical cancer screening. Papillomavirus Rep 1998;4:89-101.
  23. Kaufman R, Adam E, Icenogle J, Reeves W. Human papillomavirus testing as triage for atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions: Sensitivity, specificity, and cost-effectiveness. Am J Obstet Gynecol 1997;177:930-6.
  24. Manos M, Kinney W, Hurley L, Sherman M, Shieh-Ngai J, Kurman R, et al. Identifying women with cervical neoplasia using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999;281:1605-10.
  25. Bergeron C, Jeannel D, Poveda J, Cassonnet P, Orth G. Human Papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol 2000;95:821-7.
  26. Clavel C, Masure M, Putaud I, Thomas K, Bory J, Gabriel R, et al. Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions. J Clin Pathol 1998;51:737-40.
  27. Lin C, Tsen C, Lai C, Hsueh S, Law K. High-risk HPV DNA detection by Hybrid Capture II. J Reprod Med 2000;45:345-50.
  28. Shlay J, Dunn T, Byers T, Barón A, Douglas J. Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on Papanicolaou smears. Obstet Gynecol 2000;96:410-6.
  29. Peyton C, Schiffman M, Lorincz A, Hunt W, Mielzynska I, Bratti C, et al. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol 1998;36:3248-54.
  30. Ho G, Bierman R, Beardsley L, Chang C, Burk R. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
  31. Koutsky L, Holmes K, Critchlow C, Stevens C, Paavonen J, Beckmann A, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-78.
  32. Kim J, Wright T, Goldie S. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002;287:2382-90.
  33. Jones M. The mildly abnormal cervical smear: patient anxiety and choice of management. J R Soc Med 1996;89:257-60.
  34. Division of STD Prevention. Prevention of genital HPV infection and sequelae: Report of an external consultants\' meeting. Department of Health and Human Services, Atlanta: Centers for Disease Control and Prevention (CDC), December 1999.
  35. Clarke P, Ebel C, Catotti D, Stewart S. The psychosocial impact of human papillomavirus: Implications for health care providers. Int J STD and AIDS 1996;7:197-200.
Título español
Resumen
 Palabras clave
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

 English title
 Abstract
 Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia

Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Acerca de SIIC   Estructura de SIIC   Fuentes informativas  

Sociedad Iberoamericana de Información Científica

Copyright siicsalud© 1997-2024 ISSN siicsalud: 1667-9008
ua31517